CAS 81-25-4|cholic acid
Introduction：Basic information about CAS 81-25-4|cholic acid, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | cholic acid | ||
|---|---|---|---|
| CAS Number | 81-25-4 | Molecular Weight | 408.571 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 583.9±50.0 °C at 760 mmHg |
| Molecular Formula | C24H40O5 | Melting Point | 197-202 ºC |
| MSDS | ChineseUSA | Flash Point | 321.0±26.6 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | cholic acid |
|---|---|
| Synonym | More Synonyms |
cholic acid BiologicalActivity
| Description | Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. |
|---|---|
| Related Catalog | Natural Products >>Acids and AldehydesResearch Areas >>Metabolic Disease |
| Target | Human Endogenous Metabolite |
| In Vitro | Cholic acid competitively binds Na+/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells and significantly inhibits the uptake of Cholic acid (CA)-nanoliposomes (LPs)-Doxorubicin (DOX)-HCl, which indicates that CA-LPs-DOX-HCl are also uptaken via NTCP-mediated endocytosis pathway[1]. |
| In Vivo | Cholic acid feeding leads to increased CYP2D6 expression in CYP2D6-humanized mice. As a cholestasis model, Tg-CYP2D6 mice are fed a Cholic acid (CA)-supplemented diet for over 1 week. The treatment is known to increase bile acid pool size by 2-fold and to replace ~90% of bile acids with CA, recapitulating the features of cholestatic conditions in humans[2]. |
| Cell Assay | HepG2 cells are pretreated with the inhibitors NaN3 (1 mg/mL), Genistein (50 μg/mL), MβCD (10 mM), Nystatin (50 μg/mL), Chlorpromazine (10 μg/mL), and Cholic acid (1 mg/mL) for 30 min. After removing the inhibitors, the cells are incubated with CA-LPs for 2 h, and the cellular uptake of LPs is determined in the "In vitro cellular uptake assays" section[1]. |
| Animal Admin | Mice[2] Tg-CYP2D6 mice are fed with normal chow (control) or 1% (w/w) Cholic acid-supplemented diet (CA) for 14 days (n=4 mice/group). Alkaline phosphatase (ALP) and alanine aminotransferase (ALT) activities are measured in mouse serum. |
| References | [1]. Li Y, et al. Mechanism of hepatic targeting via oral administration of DSPE-PEG-Cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017 Feb 28;12:1673-1684. [2]. Pan X, et al. Cholic acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice. Drug Metab Dispos. 2017 Apr;45(4):346-352. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 583.9±50.0 °C at 760 mmHg |
| Melting Point | 197-202 ºC |
| Molecular Formula | C24H40O5 |
| Molecular Weight | 408.571 |
| Flash Point | 321.0±26.6 °C |
| Exact Mass | 408.287567 |
| PSA | 97.99000 |
| LogP | 2.62 |
| Vapour Pressure | 0.0±3.7 mmHg at 25°C |
| Index of Refraction | 1.558 |
| InChIKey | BHQCQFFYRZLCQQ-OELDTZBJSA-N |
| SMILES | CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C |
| Storage condition | 2-8°C |
| Water Solubility | 0.28 g/L (15 ºC) |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 4950 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Gastrointestinal - ulceration or bleeding from stomach Gastrointestinal - hypermotility, diarrhea
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 330 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
MUTATION DATA - TEST SYSTEM :
- Rodent - rat
- DOSE/DURATION :
- 7560 mg/kg/6W
- REFERENCE :
- CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 9,387,1988 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84435 No. of Facilities: 174 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 1744 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84435 No. of Facilities: 46 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 511 (estimated) No. of Female Employees: 325 (estimated)
- TEST SYSTEM :
- Rodent - rat
- DOSE/DURATION :
- 7560 mg/kg/6W
- REFERENCE :
- CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 9,387,1988 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84435 No. of Facilities: 174 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 1744 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84435 No. of Facilities: 46 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 511 (estimated) No. of Female Employees: 325 (estimated)
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319 |
| Precautionary Statements | P305 + P351 + P338 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
| Hazard Codes | Xi |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | FZ9350000 |
| HS Code | 2942000000 |
Customs
| HS Code | 2942000000 |
|---|
Articles98
More Articles| Tunable stringency aptamer selection and gold nanoparticle assay for detection of cortisol. Anal. Bioanal. Chem 406(19) , 4637-47, (2014) The first-known aptamer for the stress biomarker cortisol was selected using a tunable stringency magnetic bead selection strategy. The capture DNA probe immobilized on the beads was systematically le... | |
| Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy. Antimicrob. Agents Chemother. 54 , 1007-15, (2010) AcrAB-TolC imparts a strong intrinsic resistance phenotype to many clinically significant molecules in Escherichia coli. This complex is composed of a pump, AcrB, and a periplasmic protein, AcrA, that... | |
| Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli. Antimicrob. Agents Chemother. 51 , 923-9, (2007) AcrAB-TolC is the major, constitutively expressed tripartite multidrug efflux system in Escherichia coli that recognizes various structurally unrelated molecules, including many antibiotics, dyes, and... |
Synonyms
| Cholalic acid |
| Cholan-24-oic acid, 3,7,12-trihydroxy-, (3α,5β,7α,12α)- (9CI) |
| cholic acid |
| 17b-(1-Methyl-3-carboxypropyl)etiocholane-3a,7a,12a-triol |
| 3a,7a,12a-Trihydroxycholanic acid |
| 5β-Cholic acid |
| 3a,7a,12a-Trihydroxy-5b-cholanoic acid |
| (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| 5b-Cholic acid |
| 3a,7a,12a-Trihydroxy-5b-cholanic Acid |
| 3α,7α,12α-trihydroxy-5β-cholan-24-oic acid |
| CHOLALIN |
| MFCD00003672 |
| Cholan-24-oic acid, 3,7,12-trihydroxy-, (3α,5β,7α,8ξ,12α,20R)- |
| EINECS 201-337-8 |
| Cholbam |
| Cholic&Cyclosphorine |
| 3a,7a,12a-Trihydroxy-b-cholanic acid |
| 3a,7a,12a-Trihydroxy-β-cholanic acid |
| Cholic acd |
| 5b-Cholanic acid-3a,7a,12a-triol |
| AHR 3053-13C3 |
| (3α,5β,7α,12α)-3,7,12-Trihydroxycholan-24-oic acid |
| 3a,7a,12a-Trihydroxy-5b-cholan-24-oic Acid |
| 5β-Cholanic acid, 3α,7α,12α-trihydroxy- (7CI) |
| CHOLATE |
| Kolbam |
| UNII-G1JO7801AE |
| Orphacol |
| Cholic acid, 5β- |
| (3a,5b,7a,12a)-3,7,12-Trihydroxycholan-24-oic acid |
| Cholan-24-oic acid, 3,7,12-trihydroxy-, (3α,5β,7α,12α)- |
| Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-α,5-β,7-α,12-α)- |
| (3α,5β,7α,8ξ,12α,20R)-3,7,12-Trihydroxycholan-24-oic acid |
